Karl Balabanian

Dec 20, 2023 | nature.com | Rathana Kim |Karl Balabanian |Antoine Toubert |Nicolas Dulphy |Lionel Ades |David Fandrei

To the editor:Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marrow (BM) from clonal outgrowth, with the successive acquisition of genetic lesions. MDS are characterized by ineffective hematopoiesis leading to persistent cytopenia affecting one or more hematopoietic lineages, dysplasia, and an increased risk of transformation to acute myeloid leukemia (AML) [1].